Copertina

From Challenge to Opportunity: How Shwachman–Diamond Syndrome Became a Promising Target for Therapy Development

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Eszter S. Hars, Lisa J. McReynolds
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Clinical Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Advances in Clinical Therapies for Huntington's Disease and the Promise of Multi‐Targeted/Functional Drugs Based on Clinicaltrials.gov
di: Chunhui Huang, et al.
Pubblicazione: (2024)

Using Machine Learning to Individualize Treatment Effect Estimation: Challenges and Opportunities
di: Alicia Curth, et al.
Pubblicazione: (2024)

From the Randomized AMBORA Trial to Clinical Practice: Comparison of Medication Errors in Oral Antitumor Therapy
di: Lisa Cuba, et al.
Pubblicazione: (2024)

Harmonizing HTA Evidence Needs and Expectations: Challenges and Opportunities to Improve Evidence Generation, Ensure Access and Affordability
di: Sarah K. Emond, et al.
Pubblicazione: (2025)

Mapping the Clinical Development Trajectory of Cell and Gene Therapy Products
di: Magdi Elsallab, et al.
Pubblicazione: (2024)

Why Pediatric CAR ‐T Therapies Still Lag Behind: Insights from Six Treatments Centrally Approved in Europe
di: Lisa Hanquet, et al.
Pubblicazione: (2026)

Insights into Clinical Trials for Drugs Targeting MASLD: Progress, Challenges, and Future Directions
di: Yu Wu, et al.
Pubblicazione: (2025)

Correction to “Clinical Pharmacology and Translational Considerations in the Development of CRISPR‐Based Therapies”
Pubblicazione: (2025)

Promise of Quantitative Proteomics in the Qualification of New Approach Methodologies
di: Bhagwat Prasad
Pubblicazione: (2025)

Home Is Where the Research Is: The Promise of Decentralized Clinical Trials
di: Sarah A. Holstein
Pubblicazione: (2025)

Correction to “Promise of Quantitative Proteomics in the Qualification of New Approach Methodologies”
Pubblicazione: (2026)

The Promise of Health for All: A Collaborative Model to Close Treatment Gaps for Neglected Diseases
di: Delali Attipoe
Pubblicazione: (2024)

Challenges and Possible Strategies to Address Them in Rare Disease Drug Development: A Statistical Perspective
di: Jie Chen, et al.
Pubblicazione: (2025)

Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
di: Prathap Nagaraja Shastri, et al.
Pubblicazione: (2024)

From Classical PKPD to Model‐Informed Drug Development: Are “Digital Twins” a New Paradigm?
di: Brett E. Houk
Pubblicazione: (2026)

Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development
di: John D. Davis, et al.
Pubblicazione: (2024)

TMDD Modeling for Antibodies Directed Against Soluble Targets: Parameter Values for De Novo Modeling and Simulation From Experimental Data
di: Adam Nasim, et al.
Pubblicazione: (2026)

Optimal Trough Concentration of Tacrolimus in Pediatric Patients With Primary Nephrotic Syndrome
di: Hui Wang, et al.
Pubblicazione: (2024)

The US Food and Drug Administration's Model‐Informed Drug Development Meeting Program: From Pilot to Pathway
di: Rajanikanth Madabushi, et al.
Pubblicazione: (2024)

Cardiovascular‐Kidney‐Metabolic Syndrome in People With HIV : An Emerging Frontier for Clinical Pharmacology
di: Aaron S. Devanathan, et al.
Pubblicazione: (2025)

How Much More Efficient Are Adaptive Platform Trials Than Multiple Stand‐Alone Trials? A Comprehensive Simulation Study for Streamlining Drug Development During a Pandemic
di: Masanao Sasaki, et al.
Pubblicazione: (2024)

Epidemiological Characteristics, Target Distribution, and Clinical Value of Targeted Anticancer Drugs Approved in China: A Cross‐Sectional Study
di: Ting Zhu, et al.
Pubblicazione: (2026)

Uncovering New Therapeutic Targets for Amyotrophic Lateral Sclerosis and Neurological Diseases Using Real‐World Data
di: Mohammadali Alidoost, et al.
Pubblicazione: (2025)

Impact of Model‐Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost
di: Vaishali Sahasrabudhe, et al.
Pubblicazione: (2025)

Reflections on Model‐Informed Drug Development
di: Lawrence J. Lesko, et al.
Pubblicazione: (2024)

Ticagrelor versus Adjusted‐Dose Prasugrel in Acute Coronary Syndrome with Percutaneous Coronary Intervention
di: Ming‐Lung Tsai, et al.
Pubblicazione: (2024)

Optimal Drug, Optimal Dose, or Both in the Pharmacological Treatment of Neonatal Opioid Withdrawal Syndrome?
di: Walter K. Kraft
Pubblicazione: (2025)

Clinical Pharmacology Considerations for the “Off‐the‐Shelf” Allogeneic Cell Therapies
di: Hardik Mody, et al.
Pubblicazione: (2024)

Advances in Incretin‐Based Therapies for MAFLD: Mechanisms and Clinical Evidence
di: Wenqi Dong, et al.
Pubblicazione: (2025)

A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders
di: Pepijn P.N.M. Eijsvogel, et al.
Pubblicazione: (2026)

Tailoring Drug Therapy: Bridging Data Science and Clinical Reality
di: Karen Rowland Yeo
Pubblicazione: (2026)

Beyond Population‐Level Targets for Drug Concentrations: Precision Dosing Needs Individual‐Level Targets that Include Superior Biomarkers of Drug Responses
di: Thomas M. Polasek, et al.
Pubblicazione: (2024)

Emerging Tools and Technologies for Microbiome‐Aware Drug Development
di: Henry J. Haiser, et al.
Pubblicazione: (2025)

Development of a Multifaceted Program for Pharmacogenetics Adoption at an Academic Medical Center: Practical Considerations and Lessons Learned
di: Tyler Shugg, et al.
Pubblicazione: (2024)

Alemtuzumab Exposure and T Lymphocyte Depletion: A Population Pharmacokinetic‐Pharmacodynamic Model of Alemtuzumab Induction Therapy for Kidney Transplantation
di: Lukas K. van Vugt, et al.
Pubblicazione: (2025)

Population Pharmacokinetics of Trimethoprim/Sulfamethoxazole: Dosage Optimization for Patients with Renal Insufficiency or Receiving Continuous Renal Replacement Therapy
di: Emiel Leegwater, et al.
Pubblicazione: (2024)

Information Bias in Electronic Health Records and Administrative Claims Data: A Targeted Review of the Recent Literature
di: Patrick J. Arena, et al.
Pubblicazione: (2025)

Pharmacokinetic Modeling and Model‐Based Hypothesis Generation for Dose Optimization of Clonidine in Neonates With Neonatal Opioid Withdrawal Syndrome
di: Fei Tang, et al.
Pubblicazione: (2024)

Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy
di: Michael T. Eadon, et al.
Pubblicazione: (2025)

Personalized Chronomodulated 5‐Fluorouracil Treatment: A Physiologically‐Based Pharmacokinetic Precision Dosing Approach for Optimizing Cancer Therapy
di: Fatima Zahra Marok, et al.
Pubblicazione: (2024)